T CELL RECEPTORS AGAINST RAS WITH G12D, G12V, G13D OR Q61R MUTATION
US Application 63/673,840
Filed on 2024-07-22
Filed on 2024-07-22
DRUG-REGULATABLE, INDUCIBLE CYTOKINE EXPRESSION
US Application 63/652,871
Filed on 2024-05-29
Filed on 2024-05-29
MULTIFUNCTIONAL MOLECULES BINDING TO TCR AND USES THEREOF
US Application 63/633,193
Filed on 2024-04-12
Filed on 2024-04-12
COMPOSITIONS AND METHODS FOR THE MANIPULATION OF FUNCTIONAL LONG LIVED PLASMA CELL (LLPC) POPULATIONS AND USE THEREOF FOR TREATMENT AND MODULATION OF DISEASE
US Application 63/552,069
Filed on 2024-02-09
Filed on 2024-02-09
Methods of Determining Likelihood of Response to Anti-PD-L1 Antibodies in Lung Cancer Patients
US Application 63/640,731
Filed on 2024-04-30
Filed on 2024-04-30
Beta-Catenin Inhibitors and Degraders
(LBR License revocation underway Jan 2025)
US Application 63/564,573
Filed on 2024-03-13
Filed on 2024-03-13
OXYNITIDINE DERIVATIVES USEFUL AS TYROSYL-DNA PHOSPHODIESTERASE INHIBITORS AND RADIOSENSITIZERS
US Application 63/674,198
Filed on 2024-07-22
Filed on 2024-07-22
T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53
Hong Kong
62024096322.8
Filed on 2024-09-03
62024096322.8
Filed on 2024-09-03
METHODS TO IDENTIFY AND SELECTIVELY EXPAND TUMOR ANTIGEN-SPECIFIC
T CELLS .
US Application 63/572,693
Filed on 2024-04-01
Filed on 2024-04-01
RADIOLABELED GLYPICAN-3 (GPC3)-SPECIFIC SINGLE DOMAIN ANTIBODY AND USE THEREOF AS AN IMAGING AGENT FOR DETECTION OF GPC3-POSITIVE TUMORS
US Application 63/570,344
Filed on 2024-03-27
Filed on 2024-03-27